February 18, 2021
1 min read
Save
IMICA
Issue: February 2021
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Inhibition of the interleukin-6 mediated immune response with tolicizumab (Actemra, Genentech) vs. placebo in out-of-hospital cardiac arrest.